Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2025 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Second Quarter 2025 Results

Aptose Reports Second Quarter 2025 Results
August 06, 2025 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

• Safety Review Committee endorses escalation to 160 mg TUS dosing; no dose-limiting toxicities to date
August 01, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
July 15, 2025 17:00 ET | Source: Aptose Biosciences, Inc.

Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML

Aptose has received an additional advance of US$2.0M from Hanmi Pharmaceutical Co. as part of a US$8.5M loan facility agreement.
July 01, 2025 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose Upgraded to Trade on OTCQB Market

Aptose Upgraded to Trade on OTCQB Market
June 30, 2025 17:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Deferral of Interest Payment

Aptose Announces Deferral of Interest Payment
June 20, 2025 07:52 ET | Source: Aptose Biosciences, Inc.

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

Aptose and Hanmi Pharmaceutical Enter New Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
June 17, 2025 07:45 ET | Source: Aptose Biosciences, Inc.

Aptose Provides Corporate Updates

Aptose announces corporate updates
June 12, 2025 12:00 ET | Source: Aptose Biosciences, Inc.

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2
May 27, 2025 17:53 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Announces Results from Annual and Special Meeting of Shareholders

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right